Table 1.
Reporting of aspects of trial design, conduct and analysis: Stratified by diseases and types of Intervention
| Interventions | All | Drug | COPD | Heart failure | Diabetes | Stroke | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-drug | Drug | Non-drug | Drug | Non-drug | Drug | Non-drug | Drug | Non-drug | |||
| Number of trials | 161 | 70 | 91 | 20 | 29 | 12 | 19 | 26 | 22 | 12 | 21 |
| Reporting of between- group comparisons, % (n) | 90% (145) | 90% (63) | 89% (81) | 100% (20) | 93% (27) | 67% (8) | 95% (18) | 92% (24) | 82% (18) | 92% (11) | 86% (18) |
| Primary outcome, % (n) | 33% (53) | 50% (35) | 20% (18) | 70% (14) | 7% (2) | 17% (2) | 21% (4) | 42% (11) | 36% (8) | 67% (8) | 19% (4) |
| Primary outcome is only one measure, % (n) | 21% (34) | 31% (22) | 13% (12) | 35% (7) | 0% (0) | 8% (1) | 16% (3) | 27% (7) | 32% (7) | 58% (7) | 10% (2) |
| No statistical comparison of baseline characteristics, % (n) | 68% (110) | 79% (55) | 60% (55) | 85% (17) | 59% (17) | 83% (10) | 68% (13) | 73% (19) | 73% (16) | 75% (9) | 43% (9) |
| Reporting of handling of missing data, % (n) | 17% (28) | 21% (15) | 13% (12) | 20% (4) | 10% (3) | 8% (1) | 5% (1) | 27% (7) | 9% (2) | 25% (3) | 33% (7) |
| Intention-to-treat analysis reported, % (n) | 42% (67) | 53% (37) | 33% (30) | 70% (14)% | 24% (7) | 33% (4) | 26% (5) | 46% (12) | 27% (6) | 58% (7) | 57% (12) |
| Reporting of P values and 95% CI % (n) | 24% (38) | 31% (22) | 20% (18) | 45% (9) | 24% (7) | 8% (1) | 16% (3) | 19% (5) | 32% (7) | 58% (7) | 5% (1) |